Spark Therapeutics (ONCE) Upgraded at Wedbush

Wedbush upgraded shares of Spark Therapeutics (NASDAQ:ONCE) from an underperform rating to a neutral rating in a research note published on Wednesday, Marketbeat reports. They currently have $40.00 price objective on the biotechnology company’s stock. The analysts noted that the move was a valuation call.

A number of other research firms have also recently issued reports on ONCE. Royal Bank of Canada cut Spark Therapeutics from an outperform rating to a sector perform rating and set a $100.00 price objective on the stock. in a research report on Thursday, July 19th. Cantor Fitzgerald set a $103.00 price target on Spark Therapeutics and gave the company a buy rating in a research note on Monday, July 16th. ValuEngine lowered Spark Therapeutics from a strong-buy rating to a buy rating in a research note on Tuesday, July 24th. Raymond James set a $82.00 price target on Spark Therapeutics and gave the company a buy rating in a research note on Wednesday, August 8th. Finally, SunTrust Banks decreased their price target on Spark Therapeutics to $61.00 and set a buy rating on the stock in a research note on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $68.52.

Shares of ONCE traded down $3.24 on Wednesday, reaching $42.76. 666,734 shares of the stock traded hands, compared to its average volume of 567,755. The stock has a market cap of $1.71 billion, a PE ratio of -5.60 and a beta of 2.27. The company has a current ratio of 10.71, a quick ratio of 18.14 and a debt-to-equity ratio of 0.09. Spark Therapeutics has a 12 month low of $39.01 and a 12 month high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). The firm had revenue of $10.70 million for the quarter, compared to the consensus estimate of $27.44 million. Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.18%. The business’s revenue for the quarter was up 463.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.90) earnings per share. Equities analysts forecast that Spark Therapeutics will post -1.44 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of ONCE. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Spark Therapeutics in the third quarter worth $122,000. Bank of Montreal Can boosted its stake in Spark Therapeutics by 1,045.4% in the third quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 2,969 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Spark Therapeutics in the second quarter worth $203,000. Smith Asset Management Group LP boosted its stake in Spark Therapeutics by 39.6% in the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 1,120 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in Spark Therapeutics by 100.0% in the third quarter. SG Americas Securities LLC now owns 4,493 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 2,246 shares in the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: Inflation

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply